Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and maintenance of efficacy study of JZP-110 in excessive sleepiness associated with narcolepsy or obstructive sleep apnea
2014-005489-31Phase 3Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- May 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of solriamfetol in narcolepsy and obstructive sleep apnea hypopnea syndrome (OSAHS) (2 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Safety and tolerability, Maintenance of efficacy by ESS and 5 more. Started May 2015; status: completed.
02
Drugs
solriamfetol
03
Conditions
narcolepsyobstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on 2014-005489-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005489-31.